H Gojon1, D Fawunmi2, A Valachis3. 1. Department of Oncology, Karolinska Solna, 171 76 Stockholm, Sweden. 2. Department of Internal Medicine, Mälarsjukhuset, 63188 Eskilstuna, Sweden. 3. Department of Oncology, Mälarsjukhuset, 63188 Eskilstuna, Sweden; University of Uppsala, 751 85 Uppsala, Sweden. Electronic address: valachis@hotmail.com.
Abstract
BACKGROUND: The aim of this meta-analysis is to evaluate the role of sentinel lymph node biopsy (SLNB) in patients with microinvasive breast cancer. METHODS: We searched MEDLINE and ISI Web of Science to identify studies including patients with microinvasive breast cancer who underwent SLNB and reported the rate of sentinel-node positivity. We performed proportion meta-analysis using either fixed or random-effects model based on the between-study heterogeneity. FINDINGS: A total of 24 studies including 968 patients met the eligibility criteria. The summary estimate for the sentinel-node (SN) positivity rate was 3.2% (95% Confidence Interval (CI): 2.1%-4.6%), 4.0% (95% CI 2.7%-5.5%), and 2.9% (95% CI: 1.6%-4.6%) for macrometastasis, micrometastasis and isolated tumor cells (ITC) respectively. Significant between-study heterogeneity was observed only in the meta-analysis of ITC positivity rate. INTERPRETATION: The amount of positive sentinel node in patients with proven microinvasive breast cancer is relatively low. As a result, the indications for SLNB in these patients should be probably individualized.
BACKGROUND: The aim of this meta-analysis is to evaluate the role of sentinel lymph node biopsy (SLNB) in patients with microinvasive breast cancer. METHODS: We searched MEDLINE and ISI Web of Science to identify studies including patients with microinvasive breast cancer who underwent SLNB and reported the rate of sentinel-node positivity. We performed proportion meta-analysis using either fixed or random-effects model based on the between-study heterogeneity. FINDINGS: A total of 24 studies including 968 patients met the eligibility criteria. The summary estimate for the sentinel-node (SN) positivity rate was 3.2% (95% Confidence Interval (CI): 2.1%-4.6%), 4.0% (95% CI 2.7%-5.5%), and 2.9% (95% CI: 1.6%-4.6%) for macrometastasis, micrometastasis and isolated tumor cells (ITC) respectively. Significant between-study heterogeneity was observed only in the meta-analysis of ITC positivity rate. INTERPRETATION: The amount of positive sentinel node in patients with proven microinvasive breast cancer is relatively low. As a result, the indications for SLNB in these patients should be probably individualized.
Authors: G Cserni; C A Wells; H Kaya; P Regitnig; A Sapino; G Floris; T Decker; M P Foschini; P J van Diest; D Grabau; A Reiner; J DeGaetano; E Chmielik; A Cordoba; X Andreu; V Zolota; E Charafe-Jauffret; A Ryska; Z Varga; N Weingertner; J P Bellocq; I Liepniece-Karele; G Callagy; J Kulka; H Bürger; P Figueiredo; J Wesseling; I Amendoeira; D Faverly; C M Quinn; S Bianchi Journal: Virchows Arch Date: 2016-01-27 Impact factor: 4.064
Authors: Matthew G Davey; Colm O'Flaherty; Eoin F Cleere; Aoife Nohilly; James Phelan; Evan Ronane; Aoife J Lowery; Michael J Kerin Journal: BJS Open Date: 2022-03-08